TESLA is a multicenter trial in which patients with moderate-large acute ischemic stroke infarcts will be assigned to either best medical management alone (including intravenous recombinant tissue-type plasminogen activator (IV rtPA)) or intra-arterial treatment (IAT) with mechanical thrombectomy added to best medical management.

Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the instructions for use (IFU) and under FDA Investigational Device Exemption G190006. Patients will be enrolled at up to 35 U.S. centers and 5 European centers over an anticipated three-year period, with an additional year for trial closeout.